APTARGROUP, INC. ATR revenue by segment, product and geography
In its fiscal year ending 2025-12-31, APTARGROUP, INC. reported revenue across 3 business segments; the largest, Pharma Segment, was $1.74B, 46.0% of the filed sum (+5.7% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Pharma Segment$1.74B46.0%+5.7% yoy
- Beauty Segment$1.31B34.7%+6.8% yoy
- Closures Segment$730M19.3%+2.3% yoy
Members sum to the consolidated $3.78B for this period.
- Europe$1.86Bshare n/a+5.2% yoy
- United States$1.07Bshare n/a+3.2% yoy
- Other Europe$788Mshare n/a+5.3% yoy
- Other Foreign Countries$649Mshare n/a+4.7% yoy
- France$513Mshare n/a+2.7% yoy
- Italy$202Mshare n/a+12.1% yoy
- Spain$195Mshare n/a+13.8% yoy
- China$194Mshare n/a+25.0% yoy
- +1 more member in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Pharma Segment$458M44.6%+3.5% yoy
- Beauty Segment$367M35.8%+9.7% yoy
- Closures Segment$201M19.6%+6.5% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.